Floatz logo

Riluzole

Genitourinary Cancer

University of California, IrvineSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

15 Active assets in the Genitourinary Cancer cohort.

Asset / SponsorPhaseRating
Nivolumab
Spanish Oncology Genito-Urinary Group
Phase 2B
Tadalafil
Regina Elena Cancer Institute
Phase 3B
Ipilimumab
Dana-Farber Cancer Institute
Phase 2B
Atezolizumab
British Columbia Cancer Agency
Phase 2B
AMCASERTIB
Sumitomo Pharma America, Inc.
Phase 2CCC

View all 31 →

Same molecule, other indications

Riluzole is also rated in:

amyotrophic lateral sclerosisDormant
BB
Indicative ·
69 / 100
View asset →
major depressive disorderDormant
BB
Indicative ·
68 / 100
View asset →
cerebellar ataxiaDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →